Key facts
- This page summarizes Michael Egholm's Form 4 filing for STANDARD BIOTOOLS INC. (LAB).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 21 May 2024, 17:37.
Michael Egholm - 20 May 2024 Form 4 Insider Report for STANDARD BIOTOOLS INC. (LAB)
- Form type
- 4
- Accepted by SEC
- 21 May 2024, 17:37:39 UTC
- Previous filing
- 09 Apr 2024
- Next filing
- 05 Sep 2024
- SEC filing
- View on sec.gov
- Reporting owner signature
- /s/ Michael Egholm by Agnieszka Gallagher, Attorney-in-Fact
SEC evidence
5 source fields
Reporting owner
1 detail
Key filing fact
Michael Egholm filed Form 4 for STANDARD BIOTOOLS INC. (LAB) on 21 May 2024.
Change
- Previous filing in this sequence was filed on 09 Apr 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
See Original Filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
LAB
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +1,000,000
- Change %
- +188%
- Price
- $0.000000
- Shares after
- 1,531,592
- Date
- 20 May 2024
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
LAB
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +2,250,000
- Change %
- Price
- $0.000000
- Shares after
- 2,250,000
- Date
- 20 May 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 2,250,000
- Exercise price
- $2.58
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Represents Restricted Stock Units ("RSUs") that vest as to 1/16th of the RSUs on August 20, 2024, with the remaining RSUs vesting in equally quarterly installments over four years thereafter, subject to the Reporting Person's continued service through the applicable vesting date. Each RSU represents the right to receive one share of common stock upon vesting.
Footnote F2
The Option becomes exercisable as to 1/16th of the underlying shares on August 20, 2024, with the remaining shares vesting in equal quarterly installments over four years thereafter, subject to the Reporting Person's continued service through the applicable vesting date.